Bevatsizumab (Avastin) v lechenii bol'nykh rakom molochnoy zhelezy
- Authors: Lud AN1, Gan'shina IP1
-
Affiliations:
- Issue: No 18 (2009)
- Pages: 27-30
- Section: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/278113
- ID: 278113
Cite item
Full Text
Abstract
Рассматриваются возможности использования бевацизумаба (Авастина) в лечении диссеминированного рака молочной железы (РМЖ). Проведенные клинические исследования свидетельствуют о высокой эффективности бевацизумаба при лечении больных HER2-негативным РМЖ. Имеющиеся данные об эффективности комбинации эндокринной терапии и бевацизумаба требуют дальнейшего изучения в исследованиях III фазы. Большой интерес представляют результаты активно ведущихся исследований III фазы, в которых анализируется целесообразность применения бевацизумаба в лечении больных HER2-позитивным РМЖ в комбинации с трастузумабом и химиотерапией.
References
- Miller K, Wang M, Gralow J, et al. A randomized phase III trial of paclitaxel versus paclitaxel plus bevacizumab as first-line therapy for locally recurrent or metastatic breast cancer: a trial coordinated by the Eastern Cooperative Oncology Group (E2100). Breast Cancer Res Treat 2005;94(Suppl. 1):S6, abstr. 3.
- Cleator S, Heller W, CoombesR, et al. Triple-negative breast cancer: therapeutic options. Lancet Oncol 2007;8(3):235-44.
- Pivot X, Verma S, Thomssen C, et al. Clinical benefit of bevacizumab (BV) plus first-line docetaxel (D) in elderly patients (pts) with locally recurrent (LR) or metastatic breast cancer (mBC): AVADO study. Ann Meet Am Soc Clin Oncol 2009, abstr. 1094.
- Miller K, Chap L, Holmes F, et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 2005;23:792-99.
- Miller K, Gradishar W, Moish C, et al. Capecitabine plus bevacizumab in first line metastatic breast cancer: an interim safety and efficacy report of the first phase of Xeloda plus Avastin 1st line metastatic breast cancer trial. Breast Cancer Res Treat 2006;100(Suppl. 1):S103, abstr. 2068.
- Sledge G, Miller K, Moisa C, et al. Safety and efficacy of capecitabine (C) plus bevacizumab (B) as first-line in metastatic breast cancer. Presented at: the 43rd Annual Meeting of the American Society of Clinical Oncology; June 1-5, 2007; Chicago, FL.
- Perez E, Hillman D, Kugler J, et al. North Central Cancer Treatment Group (NCCTG) N0432: Phase II trial of docetaxel with capecitabine and bevacizumab as first line chemotherapy for patients with metastatic breast cancer. Breast Cancer Res Treat 2006;100(Suppl. 1):2069a.
- Robert N, Dieras V, Glaspy J, et al. RIBBON-1: Randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab (B) for first-line treatment of HER2-negative locally recurrent or metastatic breast cancer (MBC). ASCO Annual Meeting 2009;27(15S Suppl.):abstr. 1005.
- Rubin M, Barton J, Shipley D, et al. Efficacy results from a multicenter phase II noncomparative two-arm pilot trial of bevacizumab with anastrozole or fulvestrant as first-line endocrine therapy for metastatic breast cancer. ASCO Annual Meeting 2009, abstr. 1091.
- Traina T, Rugo H, Caravelli J, et al. Feasibility Trial of Letrozole in Combination With Bevacizumab in Patients With Metastatic Breast Cancer. J Clin Oncol 2009;27.
- Ryan P, Tung N, Isakoff S, et al. Neoadjuvant cisplatin and bevacizumab in triple negative breast cancer (TNBC): Safety and efficacy. 45th American Society of Clinical Oncology Annual Meeting 2009.
- Forero-Torres A, Galleshaw J, Jones C, et al. A pilot open-label trial of preoperative (neoadjuvant) letrozole in combination with bevacizumab in postmenopausal women with newly diagnosed operable breast cancer. J Clin Oncol 2008;26(Suppl.):abstr. 625.
Supplementary files
